Antisense Research and Application

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Handbook of Experimental Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/978-3-642-58785-6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Antisense properties of peptide nucleic acid.

  1999cited by this paper
• The Molecular Biology of Chronic Myeloid Leukaemia

  1998cited by this paper
• Methotrexate treatment for Crohn's disease.

  1998cited by this paper
• Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture.

  1998cited by this paper
• Microinjection of antisense oligonucleotides and electrophysiological recording of whole-cell currents as tools to identify specific G-protein subtypes coupling hormone receptors to voltage-gated calcium channels.

  1998cited by this paper
• Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.

  1998cited by this paper
• Crystal structure of a peptide nucleic acid (PNA) duplex at 1.7 Å resolution

  1997cited by this paper
• Mixed-Backbone Oligonucleotides Containing Phosphorothioate and Methylphosphonate Linkages as Second Generation Antisense Oligonucleotide

  1997cited by this paper
• Histological Localization of Phosphorothioate Oligodeoxynucleotides in Normal Rodent Tissue

  1997cited by this paper
• Advances in understanding the pharmacological properties of antisense oligonucleotides.

  1997cited by this paper
• Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

  1997cited by this paper
• An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

  1997cited by this paper
• Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 Mice

  1997cited by this paper
• RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.

  1997cited by this paper
• Phosphorothioate oligonucleotides: Largely reduced (N-1)-mer and phosphodiester content through the use of dimeric phosphoramidite synthons

  1997cited by this paper
• Putative roles for the inducible transcription factor c-fos in the central nervous system: studies with antisense oligonucleotides.

  1997cited by this paper
• Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids.

  1997cited by this paper
• Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

  1997cited by this paper
• Characterization and Modulation of Immune Stimulation by Modified Oligonucleotides

  1997cited by this paper
• Cleavage of Single Strand RNA Adjacent to RNA-DNA Duplex Regions by Escherichia coli RNase H1*

  1997cited by this paper
• DNA antisense therapy for asthma in an animal model

  1997cited by this paper
• Vascular System Defects and Impaired Cell Chemokinesis as a Result of Gα13 Deficiency

  1997cited by this paper
• Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.

  1997cited by this paper
• Synthesis and Properties of the Oligonucleotide N3′ →P5′ Phosphoramidates

  1997cited by this paper
• Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.

  1997cited by this paper
• Concept, Discovery and Development of MMI Linkage: Story of a Novel Linkage: for Antisense Constructs

  1997cited by this paper
• Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras.

  1997cited by this paper
• Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.

  1997cited by this paper
• Structural analysis of DNA bending induced by tethered triple helix forming oligonucleotides.

  1997cited by this paper
• Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents.

  1997cited by this paper
• Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

  1997cited by this paper
• Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.

  1997cited by this paper
• Synthesis and Evaluation Of 2″-Modified MMI Linked Dimers in Antisense Constructs

  1997cited by this paper
• Sequence-specific alkylation and cleavage of DNA mediated by purine motif triple helix formation.

  1996cited by this paper
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• Inhibition of human telomerase activity by peptide nucleic acids

  1996cited by this paper
• Transcription-mediated binding of peptide nucleic acid (PNA) to double-stranded DNA: sequence-specific suicide transcription.

  1996cited by this paper
• Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.

  1996cited by this paper
• Proof of Mechanism of Antisense Drugs

  1996cited by this paper
• Solution structure of a pyrimidine-purine-pyrimidine triplex containing the sequence-specific intercalating non-natural base D3.

  1996cited by this paper
• Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys.

  1996cited by this paper
• Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells. Potential role of FGF and PDGF.

  1996cited by this paper
• Fate of cationic liposomes and their complex with oligonucleotive in vivo

  1996cited by this paper
• Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat.

  1996cited by this paper
• Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.

  1996cited by this paper
• Unwinding of the third strand of a DNA triple helix, a novel activity of the SV40 large T-antigen helicase.

  1996cited by this paper
• Triplex formation at physiological pH by 5-Me-dC-N4-(spermine) [X] oligodeoxynucleotides: non protonation of N3 in X of X*G:C triad and effect of base mismatch/ionic strength on triplex stabilities.

  1996cited by this paper
• Chemical methods of DNA and RNA fluorescent labeling.

  1996cited by this paper
• A new class of genome rare cutters

  1996cited by this paper
• A specific Go heterotrimer couples somatostatin receptors to voltage‐gated calcium channels in RINm5F cells

  1996cited by this paper
• Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.

  1996cited by this paper
• Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice

  1996cited by this paper
• Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus

  1996cited by this paper
• Antisense properties of duplex- and triplex-forming PNAs.

  1996cited by this paper
• Quinazoline-2,4(1H,3H)-dione as a substitute for thymine in triple-helix forming oligonucleotides: a reassessment.

  1996cited by this paper
• Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1

  1996cited by this paper
• Progress in antisense oligonucleotide therapeutics.

  1996cited by this paper
• Distamycin A complexation with a nucleic acid triple helix.

  1996cited by this paper
• Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.

  1996cited by this paper
• Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice.

  1996cited by this paper
• Triplex formation by oligonucleotides containing novel deoxycytidine derivatives [published erratum appears in Nucleic Acids Res 1997 Sep 15;25(18): following 3750]

  1996cited by this paper
• A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

  1996cited by this paper
• The design of an agent to bend DNA.

  1996cited by this paper
• Antisense oligonucleotides: towards clinical trials.

  1996cited by this paper
• Activation of human B cells by phosphorothioate oligodeoxynucleotides.

  1996cited by this paper
• Triplex‐Mediated, in vitro Targeting of Psoralen Photoadducts within the Genome of a Transgenic Mouse

  1996cited by this paper
• Processing of chimeric antisense oligonucleotides by human vascular smooth muscle cells and human atherosclerotic plaque. Implications for antisense therapy of restenosis after angioplasty.

  1996cited by this paper
• Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA

  1996cited by this paper
• Null Mutation of c-fos Impairs Structural and Functional Plasticities in the Kindling Model of Epilepsy

  1996cited by this paper
• Unambiguous structure characterization of a DNA-RNA triple helix by 15N- and 13C-filtered NOESY spectroscopy.

  1996cited by this paper
• Use of a pyrimidine nucleoside that functions as a bidentate hydrogen bond donor for the recognition of isolated or contiguous G-C base pairs by oligonucleotide-directed triplex formation.

  1996cited by this paper
• Quantitation of phosphorothioate oligonucleotides in human plasma.

  1996cited by this paper
• Triple Helix-forming Oligonucleotide Corresponding to the Polypyrimidine Sequence in the Rat 1(I) Collagen Promoter Specifically Inhibits Factor Binding and Transcription (*)

  1996cited by this paper
• Microscopic DNA Flexibility Analysis

  1996cited by this paper
• Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant.

  1996cited by this paper
• Prediction of the stability of DNA triplexes.

  1996cited by this paper
• 2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides.

  1996cited by this paper
• Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.

  1996cited by this paper
• Mutagenesis in Mammalian Cells Induced by Triple Helix Formation and Transcription-Coupled Repair

  1996cited by this paper
• Stable triple helices formed by oligonucleotide N3'-->P5' phosphoramidates inhibit transcription elongation.

  1996cited by this paper
• Binding of DNA oligonucleotides to sequences in the promoter of the human bc1-2 gene.

  1996cited by this paper
• Intrastriatally injected c-fos antisense oligonucleotide interferes with striatonigral but not striatopallidal gamma-aminobutyric acid transmission in the conscious rat.

  1996cited by this paper
• Intramolecular G-quartet Motifs Confer Nuclease Resistance to a Potent Anti-HIV Oligonucleotide (*)

  1996cited by this paper
• Transforming growth factor‐β‐mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides

  1996cited by this paper
• A Simple Method for Delivering Morpholino Antisense Oligos into the Cytoplasm of Cells

  1996cited by this paper
• Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.

  1996cited by this paper
• Sequence specificity of triplex DNA formation: Analysis by a combinatorial approach, restriction endonuclease protection selection and amplification.

  1996cited by this paper
• Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed Rabbits*

  1996cited by this paper
• Comparative pharmacokinetics of antisense oligonucleotides.

  1996cited by this paper
• Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis.

  1996cited by this paper
• Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet.

  1996cited by this paper
• Structural features and stability of an RNA triple helix in solution.

  1996cited by this paper
• Calorimetric analysis of triple helices targeted to the d(G3A4G3).d(C3T4C3) duplex.

  1996cited by this paper
• Interstrand complex formation of purine oligonucleotides and their nonionic analogs: the model system of d(AG)8 and its complement, d(CT)8.

  1996cited by this paper
• Control of scarring in adult wounds using antisense transforming growth factor‐β1 oligodeoxynucleotides

  1996cited by this paper
• Solution structure of a peptide nucleic acid–DNA duplex

  1996cited by this paper
• Diversity and selectivity of receptor-G protein interaction.

  1996cited by this paper
• Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits.

  1996cited by this paper
• 8 Oligonucleotide N3 ′ (cid:1) P5 ′ phosphoramidates as antisense

  1996cited by this paper
• Helical periodicity of GA-alternating triple-stranded DNA.

  1996cited by this paper

• Stereocontrolled access to thioisosteres of nucleoside di- and triphosphates

  2023cites this paper
• Stereocontrolled Radical Thiophosphorylation.

  2023cites this paper
• Chemistry, structure and function of approved oligonucleotide therapeutics

  2023cites this paper
• Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome

  2022cites this paper
• A combined experimental and computational study on peptide nucleic acid (PNA) analogues of tumor suppressive miRNA-34a.

  2019cites this paper
• Antisense therapies for movement disorders

  2019cites this paper
• Variants de hsd17b13 et utilisations correspondantes

  2018cites this paper
• Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante

  2018cites this paper
• NMR 1H-Shielding Constants of Hydrogen-Bond Donor Reflect Manifestation of the Pauli Principle

  2018cites this paper
• Substances et méthodes pour le traitement d'une immunodéficience combinée sévère (idcs) ou syndrome d'omenn

  2017cites this paper
• Matériaux et méthodes de traitement de troubles liés à la douleur

  2017cites this paper
• Matériaux et procédés de traitement de la sclérose latérale amyotrophique et/ou de la dégénérescence lobaire frontotemporale

  2016cites this paper
• Inhibiteurs de citrine pour le traitement du cancer

  2016cites this paper
• Matériaux et méthodes de traitement d'une déficience en antitrypsine alpha-1

  2016cites this paper
• Hétérodimères dans l'immunité de l'interleukine 12b (p40) de type antigène lymphocytaire cd5 (cd5l)

  2016cites this paper
• Matériaux et méthodes pour traiter la dystrophie musculaire de duchenne

  2016cites this paper
• Thérapie enzymatique substitutive et thérapie antisens pour la maladie de pompe

  2015cites this paper
• Oligonucléotides antisens utilisés dans le traitement de la maladie de pompe

  2015cites this paper
• Anticorps anti-bb du facteur de complement

  2015cites this paper
• Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b

  2015cites this paper
• Conjugués glucidiques d'oligonucléotides antimir-22

  2014cites this paper
• Conjugués glucidiques d'oligonucléotides d'acides nucléiques bloqués

  2014cites this paper
• Modulateurs de microarn de la thermogenèse

  2013cites this paper
• Diagnostic du cancer au moyen de biomarqueurs

  2013cites this paper
• Microarn pour la génération d'astrocytes

  2013cites this paper
• Compositions et méthodes pour moduler l'expression de bdnf

  2013cites this paper
• Aptamères, aptamères multimères et leurs utilisations

  2013cites this paper
• Verfahren und zusammensetzungen zur rna-gesteuerten ziel-dna-modifikation und zur rna-gesteuerten transkriptionsmodulation

  2013cites this paper
• Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)

  2013cites this paper
• Conjugués d'oligonucléotides

  2013cites this paper
• Modulation de l'expression de l'apolipoprotéine ciii (apociii)

  2012cites this paper
• Complexes oligomère-conjugué et leur utilisation

  2012cites this paper
• Discrete assembly of synthetic peptide-DNA triplex structures from polyvalent melamine-thymine bifacial recognition.

  2012cites this paper
• Riborégulateurs répondant aux fluorures, transporteurs de fluorure et procédés d'utilisation

  2012cites this paper
• Procédés de modulation de l'expression de kallicréine (klkb1)

  2012cites this paper
• Microarn dans des maladies neurodégénératives

  2012cites this paper
• Composés antisens sélectifs et utilisations de ceux-ci

  2012cites this paper
• Composés oligonucléotidiques multimères

  2012cites this paper
• Traitement des maladies associées à la frataxine (fxn) par inhibition de la transcription de l'anti-sens naturel de la fxn

  2012cites this paper
• New Antisense Strategies: Chemical Synthesis of RNA Oligomers

  2011cites this paper
• Structure polynucléotidique réticulée

  2011cites this paper
• Modulation de l'expression de l'analogue de l'angiopoïétine 3

  2011cites this paper
• Dosage quantitatif d'hélicase

  2011cites this paper
• Procédés de préparation de nucléosides de purine 2'-o-substitués

  2011cites this paper
• Compositions et procédés d'inhibition de l'expression de gènes ikk2

  2011cites this paper
• Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen

  2011cites this paper
• Traitement de maladies liées à la sirtuine (sirt) par inhibition du transcrit antisens naturel d'une sirtuine (sirt)

  2011cites this paper
• Antagonistes de composant du complément 8-bêta (c8-bêta) et utilisations associées

  2011cites this paper
• Modifizierte nukleoside, analoga davon und daraus hergestellte oligomere verbindungen

  2011cites this paper
• Traitement de maladies associées à l'alpha-l-iduronidase (idua) par inhibition du transcrit antisens endogène de idua

  2011cites this paper
• Synthesis and properties of carbohydrate–phosphate backbone-modified oligonucleotide analogues and nucleic acid mimetics

  2011cites this paper
• Dimeric Fe-Co Phthalocyanine Complex as a Reagent for the Selective Damage of Nucleic Acids

  2011cites this paper
• Polycombassoziierte nichtcodierende rnas

  2011cites this paper
• Selektive reduktion von allelvarianten

  2011cites this paper
• Riborégulateurs, motifs et composés régulés par la di-gmp-ii cyclique, et procédés pour leur utilisation

  2011cites this paper
• Traitement de maladies associees au regulateur du developpement lie a l'interferon 1 (ifrd1), par l'inhibition du produit de la transcription antisens naturel de l'ifrd1

  2011cites this paper
• Traitement de maladies liées à la tristétraproline (ttp) par l'inhibition d'un transcrit antisens naturel de ttp

  2010cites this paper
• Préparation lipidique améliorée

  2010cites this paper
• Modulation de l'expression de la huntingtine

  2010cites this paper
• Compositions utilisées pour l'administration d'acides nucléiques

  2010cites this paper
• Traitement de maladies associées à la protéine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2

  2010cites this paper
• Procédé d'édition de l'adn dans une cellule et constructions ayant cette capacité

  2010cites this paper
• Compositions pour lutter contre les acariens varroa chez l'abeille

  2010cites this paper
• Design of Functional Diversity in Oligonucleotides via Zwitter-Ionic Derivatives of Deprotected Oligonucleotides

  2010cites this paper
• Traitement de maladies liées à la protéine tumorale 63 (p63) par l'inhibition du produit de transcription antisens naturel de p63

  2010cites this paper
• Traitement de maladies associées à un gène antiviral grâce à l'inhibition d'un produit de transcription antisens naturel d'un gène antiviral

  2010cites this paper
• Traitement de maladies liées à un facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du transcrit antisens naturel de bdnf

  2010cites this paper
• Binding of Dumbbell Oligonucleotides to MoMuLV Reverse Transcriptase: Inhibitory Properties of RNase H Activity

  2010cites this paper
• Traitement des maladies associées au facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du produit antisens naturel de la transcription en bdnf

  2010cites this paper
• Traitement des maladies liées au facteur de transcription e3 (tfe3) et au substrat récepteur d'insuline 2 (irs2) par inhibition du transcript antisens naturel du tfe3

  2010cites this paper
• Traitement de maladies liées à un gène suppresseur de tumeur par inhibition d'un transcrit antisens naturel du gène

  2009cites this paper
• Sting (stimulateur de genes d'interferons), un regulateur de reponses immunitaires innees

  2009cites this paper
• Traitement de maladies liées à sirtuine 1 (sirt1) par inhibition d'un transcrit antisens naturel de sirtuine 1

  2009cites this paper
• Oligonucléotides antissens dirigés contre le facteur de croissance des tissus conjonctifs et utilisation de ceux-ci

  2009cites this paper
• Polypeptides et polynucléotides, et leurs utilisations en tant que médicament cible pour produire des médicaments et des agents biologiques

  2008cites this paper
• Binding properties of positively charged deoxynucleic guanidine (DNG), AgTgAgTgAgT and DNG/DNA chimeras to DNA.

  2008cites this paper
• Nanoparticules fonctionnalisées d'acide nucléique pour applications thérapeutiques

  2008cites this paper
• Riborégulateurs (riboswitches) et procédés et compositions à utiliser avec les riborégulateurs

  2008cites this paper
• Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs

  2008cites this paper
• Solid-Phase Synthesis of Modified Oligonucleotides

  2007cites this paper
• Unusual thermal stability of RNA/[RP-PS]-DNA/RNA triplexes containing a homopurine DNA strand.

  2007cites this paper
• Evidence for the formation of isothiocyanate during sulfurisation of phosphines and phosphites using xanthane hydride

  2007cites this paper
• Procédé de détection de maladies et états pathologiques oculaires et traitement de ceux-ci

  2007cites this paper
• Cibler la régulation du VEGF-B des transporteurs d'acides gras afin de moduler les maladies humaines

  2007cites this paper
• A versatile method for the preparation of conjugates of peptides with DNA/PNA/analog by employing chemo-selective click reaction in water

  2007cites this paper
• CATIONIC LIPIDS USED IN NON-VIRAL GENE DELIVERY SYSTEMS

  2007cites this paper
• Pharmazeutische Zusammensetzung mit Anti-miRNA-Antisense-Oligonukleotiden

  2007cites this paper
• Agent prophylactique/therapeutique pour le cancer

  2007cites this paper
• Composition à base de microsphères destinée à la prévention et/ou inversion de nouveaux cas de diabète auto-immun

  2007cites this paper
• Composés anti-connexine et utilisations associées à une procédure de transplantation ou de greffe

  2006cites this paper
• Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules

  2006cites this paper
• Enhanced P-stereodependent stability of complexes formed by phosphorothioate oligonucleotides due to involvement of sulfur as strong hydrogen bond acceptor

  2006cites this paper
• Ciblage du PAX2 pour l'induction de l'immunité à la tumeur à médiation DEFB1 et le traitement contre le cancer

  2006cites this paper
• Composés peptidomimétiques à activité anti-connexine et utilisations thérapeutiques

  2006cites this paper
• Unusual chromatographic behavior of oligonucleotide sequence isomers on two different anion exchange HPLC columns.

  2006cites this paper
• Verfahren und Zusammensetzungen zur Modulation der Gefäßintegrität

  2006cites this paper
• Procèdès a utiliser dans la modulation de MIR-122a

  2006cites this paper
• Immunisation d'oiseaux par administration de vaccins a vecteurs non repliquants

  2006cites this paper
• Composés anti-connexine et utilisations associées

  2006cites this paper
• Procédés et combinaisons de sonde pour détecter un mélanome

  2006cites this paper